Dual add-on therapy of gemigliptin and dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin alone: The SOLUTION 2 study.
Kyung Ah HanYou Cheol HwangShin Je MoonHo Chan ChoHye Jin YooSung Hee ChoiSuk ChonKyoung-Ah KimTae Nyun KimJun Goo KangCheol-Young ParkJong Chul WonEunjoo ChoJeongyun KimKyong-Soo ParkPublished in: Diabetes, obesity & metabolism (2024)
These results suggest that the addition of GEMI + DAPA to metformin as triple combination therapy was effective, safe and well-tolerated, especially for T2D patients who experienced poor glycaemic control on metformin alone.